Targets › PARP1
57 programs from 49 companies in 371 trials: 168 Phase 2, 150 Phase 1, 46 Phase 3, 7 Phase 4; Oncology, Other, Genitourinary; next expected readout Nov 2026.
Poly-ADP-ribosyltransferase that mediates poly-ADP-ribosylation of proteins and plays a key role in DNA repair. Mediates glutamate, aspartate, serine, threonine, histidine or tyrosine ADP-ribosylation of proteins: the ADP-D-ribosyl group of NAD(+) is transferred to the acceptor carboxyl group of target residues and further ADP-ribosyl groups are transferred to the 2'-position of the terminal adenosine moiety,…. (UniProt, P09874)
Open in Phaseline: the race on PARP1, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| AstraZeneca | Olaparib PARP 1, 2 and 3 inhibitor | PARP1, PARP3, PARP2 | Phase 4 | Metastatic Castration-resistant Prostate Cancer; Advanced Ovarian Cancer; Platinum Sensitive; Endometrial Neoplasms … | Nov 2026 |
| M.D. Anderson Cancer Center | [18F]-4FN PARP 1, 2 and 3 inhibitor | PARP1, PARP3, PARP2, CHRNB2, CHRNA4, Tubulin, OPRM1, CD274 | Phase 4 | Lymphoma; Tobacco Use Cessation; Cigarette Smoking-Related Carcinoma; Hematopoietic and Lymphoid Cell Neoplasm … | Dec 2026 |
| GSK | Niraparib Poly [ADP-ribose] polymerase 2 inhibitor; Poly [ADP-ribose] polymerase-1 inhibitor | PARP2, PARP1 | Phase 3 | Neoplasms, Breast; Ovarian Neoplasms; Neoplasms | Dec 2026 |
| Guangdong Provincial People's Hospital | Fuzuloparib PARP inhibitor | PARP1, PARP2 | Phase 3 | Triple-negative Breast Cancer | Dec 2026 |
| Jiangsu HengRui Medicine | Fuzuloparib PARP inhibitor | PARP1, PARP2 | Phase 3 | Metastatic Castration-Resistant Prostate Cancer (mCRPC) | Dec 2026 |
| Johnson & Johnson (Janssen) | Niraparib Poly [ADP-ribose] polymerase 2 inhibitor; Poly [ADP-ribose] polymerase-1 inhibitor | PARP2, PARP1 | Phase 3 | Prostatic Neoplasms; Castration-Resistant Prostatic Cancer; Prostatic Neoplasms, Castration-Resistant; Ovarian Cancer … | Dec 2026 |
| Pfizer | Talazoparib Poly [ADP-ribose] polymerase 2 inhibitor; Poly [ADP-ribose] polymerase-1 inhibitor | PARP2, PARP1 | Phase 3 | Advanced Malignancies; mCRPC; Prostate Cancer; Urothelial Carcinoma … | Dec 2026 |
| BeiGene | Pamiparib (BGB-290) Poly [ADP-ribose] polymerase-1 inhibitor; Poly [ADP-ribose] polymerase 2 inhibitor | PARP1, PARP2 | Phase 3 | Ovarian Cancer; Locally Advanced Prostate Cancer; Head and Neck Cancer; Glioblastoma | Jan 2027 |
| Alliance for Clinical Trials in Oncology | Rucaparib camsylate PARP 1, 2 and 3 inhibitor | PARP1, PARP3, PARP2 | Phase 3 | Castration-Resistant Prostate Carcinoma | Mar 2027 |
| Fudan University | Fluzoparib PARP inhibitor | PARP1, PARP2 | Phase 3 | Neoadjuvant Therapy; Breast Cancer; Breast Cancer Metastatic | Apr 2027 |
| The Netherlands Cancer Institute | ddAC-CP-Olaparib PARP 1, 2 and 3 inhibitor | PARP1, PARP2, PARP3 | Phase 3 | Breast Cancer; Cancer; Ovarian Cancer | May 2027 |
| Merck & Co. (MSD) | Olaparib PARP 1, 2 and 3 inhibitor | PARP1, PARP3, PARP2 | Phase 3 | Lung Neoplasms; Small Cell Lung Cancer; Solid Tumors; Advanced Solid Neoplasms … | May 2027 |
| AstraZeneca | Saruparib PARP inhibitor | PARP1, PARP2 | Phase 3 | Metastatic Castration-Sensitive Prostate Cancer; Advanced Breast Cancer; Metastatic Hormone-Sensitive Prostate Cancer (mHSPC); Prostate Cancer … | Sep 2027 |
| Tesaro | Niraparib Poly [ADP-ribose] polymerase 2 inhibitor; Poly [ADP-ribose] polymerase-1 inhibitor | PARP2, PARP1 | Phase 3 | Ovarian Neoplasms | Apr 2029 |
| Tongji Hospital | Fluzoparib PARP inhibitor | PARP1, PARP2 | Phase 3 | Ovarian Cancer | May 2030 |
| pharmaand | Rucaparib PARP 1, 2 and 3 inhibitor | PARP1, PARP3, PARP2 | Phase 3 | Epithelial Ovarian Cancer; Leiomyosarcoma; Peritoneal Cancer; Adenocarcinoma of the Oesophagus … | Dec 2030 |
| Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Fluorizoparib PARP1/2 inhibitor | PARP1, PARP2 | Phase 3 | Metastatic Breast Cancer | Mar 2031 |
| Impact Therapeutics | IMP4297 PARP inhibitor | PARP1, PARP2 | Phase 3 | Ovarian Cancer | – |
| National Cancer Institute (NCI) | Veliparib PARP 1, 2 and 3 inhibitor | PARP1, PARP3, PARP2 | Phase 2 | Acute Myeloid Leukemia; Glioblastoma; Locally Advanced Pancreatic Adenocarcinoma; Recurrent Lung Small Cell Carcinoma … | Nov 2026 |
| Ruijin Hospital | Fluzoparib PARP inhibitor | PARP1, PARP2 | Phase 2 | Sarcoma | Dec 2026 |
| M.D. Anderson Cancer Center | Talazoparib Tosylate Poly [ADP-ribose] polymerase 2 inhibitor; Poly [ADP-ribose] polymerase-1 inhibitor | PARP2, PARP1 | Phase 2 | Prostate Cancer; Advanced Malignant Neoplasm; Malignant Female Reproductive System Neoplasm; Advanced Malignant Solid Neoplasm | Dec 2026 |
| Memorial Sloan Kettering Cancer Center | Temozolomide PARP inhibitor | PARP1 | Phase 2 | Glioma; Newly Diagnosed Ewing Sarcoma | Jan 2027 |
| Allarity Therapeutics | 2X-121 Poly [ADP-ribose] polymerase-1 inhibitor; Poly [ADP-ribose] polymerase 2 inhibitor; Tankyrase 1/2 inhibitor | PARP1, PARP2, TNKS2, TNKS | Phase 2 | Advanced Ovarian Cancer | Mar 2027 |
| VIVUS | VI-0609 Alkylating agent; nitrosourea | PARP1 | Phase 2 | Lymphoma | Mar 2027 |
| Sun Yat-sen University | Temozolomide PARP inhibitor | PARP1, PARP2 | Phase 2 | Ewing Sarcoma | Apr 2027 |
| Peking University People's Hospital | Fluzoparib PARP inhibitor | PARP1 | Phase 2 | Germline BRCA-mutated HER2-negative Breast Cancer | Apr 2027 |
| Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Senaparib PARP inhibitor | PARP1 | Phase 2 | Ovary Cancer | Oct 2027 |
| Tianjin Medical University Cancer Institute and Hospital | Fluzoparib Poly (ADP-ribose) polymerase (PARP) inhibitor | PARP1, PARP2 | Phase 2 | Platinum-sensitive | Nov 2027 |
| Yonsei University | Nesuparib PARP inhibitor | PARP1 | Phase 2 | Endometrial Cancer | Dec 2027 |
| Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau | Nicotinamide (NAM) NAD+ precursor; promotes NAD+ biosynthesis and may support cellular metabolism and anti-in | PARP1, NAD1, NAMPT | Phase 2 | Fatty Liver | Dec 2027 |
| Fujian Cancer Hospital | Fuzuloparib PARP inhibitor | PARP1, PARP2 | Phase 2 | Ovarian Neoplasms | Dec 2027 |
| AstraZeneca | AZD5305 PARP inhibitor | PARP1, PARP2 | Phase 1 | Prostate Cancer; Adv Solid Malig - H&N SCC, ATM Pro / Def NSCLC, Gastric, Breast and Ovarian Cancer; Ovarian Cancer; Breast Cancer … | Nov 2026 |
| Chia Tai Tianqing Pharmaceutical Group | TQB3122 Capsules PARP1 inhibitor | PARP1 | Phase 1 | Advanced Cancer | Dec 2026 |
| Hangzhou SynRx Therapeutics Biomedical Technology | SYN818 PARP inhibitor | PARP1 | Phase 1 | Advanced Solid Cancer; Metastatic Solid Tumor | Dec 2026 |
| Jun Guo | Fluzoparib PARP inhibitor | PARP1, PARP2 | Phase 1 | Melanoma | Dec 2026 |
| DIGMBIO | DM5167 PARP-1 inhibitor | PARP1 | Phase 1 | Advanced Breast Cancer | Jan 2027 |
| Daewoong Pharmaceutical | Olaparib (DWZ2501) PARP 1, 2 and 3 inhibitor | PARP1, PARP3, PARP2 | Phase 1 | Cancer | Mar 2027 |
| Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | Niraparib Tosylate Monohydrate Poly [ADP-ribose] polymerase 2 inhibitor; Poly [ADP-ribose] polymerase-1 inhibitor | PARP2, PARP1 | Phase 1 | Ovarian Cancer | Mar 2027 |
| Eikon Therapeutics | IMP1734 PARP1 selective inhibitor | PARP1 | Phase 1 | Advanced Solid Tumor | Jun 2027 |
| Memorial Sloan Kettering Cancer Center | PARPi-FL PARP inhibitor-based fluorescent imaging dye | PARP1, PARP2 | Phase 1 | Oral Squamous Cell Carcinoma (OSCC) | Jul 2027 |
| Abramson Cancer Center at Penn Medicine | [18F]FluorThanatrace PARP-1 targeted PET imaging agent | PARP1 | Phase 1 | Breast Cancer; Neuroendocrine Carcinoma Metastatic; Suspected Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | Jul 2027 |
| Memorial Sloan Kettering Cancer Center | [18F]-PARPi PARP inhibitor-based PET imaging agent | PARP1, PARP2 | Phase 1 | Head and Neck Cancer | Aug 2027 |
| AstraZeneca | Palacaparib (AZD9574) PARP inhibitor | PARP1, PARP2 | Phase 1 | Breast Cancer; Advanced Solid Malignancies; Metastatic Prostate Cancer | Sep 2027 |
| University of Washington | Fluorine F 18 Fluorthanatrace PARP1-targeted radiotracer for PET imaging | PARP1 | Phase 1 | Anatomic Stage IV Breast Cancer AJCC v8 | Dec 2027 |
| Shanghai SciBrunch Therapeutics | SPR1020 PARP1 inhibitor | PARP1 | Phase 1 | Advanced Solid Tumors | Feb 2028 |
| Nerviano Medical Sciences | atamparib PARP inhibitor | PARP1 | Phase 1 | NSCLC Adenocarcinoma | Jul 2028 |
| Duke Street Bio | DSB2455 PARP1 selective inhibitor | PARP1 | Phase 1 | Advanced Cancers (Breast, Ovarian, mCRPC, Pancreatic Ductal Adenocarcinoma (PDAC), Brain Mets) With Specific Mutations (Homologous Recombination Deficiency) | Aug 2028 |
| Eikon Therapeutics | EIK1004 (IMP1707) PARP1 selective inhibitor | PARP1 | Phase 1 | Advanced Solid Tumors | Dec 2028 |
| Acerand Therapeutics (Shanghai) | ACE-86225106 PARP inhibitor | PARP1, PARP2 | Phase 1 | Solid Tumor, Adult | Dec 2028 |
| Haisco Pharmaceutical Group | HSK46256 PARP1 inhibitor | PARP1 | Phase 1 | Advanced Solid Tumor (Phase 1) | Dec 2028 |
| Fundación de investigación HM | 177Lu-DOTATATE (Lutathera®) PARP inhibitor | PARP1 | Phase 1 | Solid Tumor Cancer | Jul 2029 |
| VA Office of Research and Development | Stenoparib/Temozolomide PARP inhibitor plus alkylating agent | PARP1, PARP2 | Phase 1 | Relapsed Small Cell Lung Cancer | Dec 2029 |
| AstraZeneca | AZD4956 PARP inhibitor | PARP1, PARP2 | Phase 1 | Solid Tumours | Mar 2030 |
| Xing Xie | Fuzuloparib PARP inhibitor | PARP1, PARP2 | Phase 1 | Efficacy and Safety | – |
| Jiangsu Hansoh Pharmaceutical | HS-10502 PARP1-specific selective inhibitor | PARP1 | Phase 1 | Ovarian Cancer; Recurrent Ovarian Cancer | – |
| Boryung Pharmaceutical | Olaparib (BR2022) PARP 1, 2 and 3 inhibitor | PARP1, PARP3, PARP2 | Phase 1 | Ovarian Cancer | – |
| Zhejiang Yangli Pharmaceutical Technology | VB15010 PARP1 inhibitor | PARP1 | Phase 1 | Cancer | – |
Ovarian Cancer (26) Breast Cancer (18) Prostate Cancer (12) Advanced Malignant Solid Neoplasm (10) Acute Myeloid Leukemia (9) Endometrial Cancer (5) Advanced Breast Cancer (5) Glioblastoma (5) Metastatic Prostate Cancer (5) Metastatic Breast Cancer (4) Metastatic Castration-resistant Prostate Cancer (4) Glioma (4)
small molecule (43), mixed (10), antibody (4)
AstraZeneca (5) Memorial Sloan Kettering Cancer Center (3) Eikon Therapeutics (2) M.D. Anderson Cancer Center (2) Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University (1) Haisco Pharmaceutical Group (1) Hangzhou SynRx Therapeutics Biomedical Technology (1) Merck & Co. (MSD) (1) Nerviano Medical Sciences (1) Abramson Cancer Center at Penn Medicine (1) Tianjin Medical University Cancer Institute and Hospital (1) National Cancer Institute (NCI) (1) Pfizer (1) Johnson & Johnson (Janssen) (1) Tongji Hospital (1) VA Office of Research and Development (1) Jun Guo (1) Jiangsu Hansoh Pharmaceutical (1) Ruijin Hospital (1) Chia Tai Tianqing Pharmaceutical Group (1)
PARP2 (37) PARP3 (9) NAD1 (1) NAMPT (1) TNKS2 (1) TNKS (1) CHRNB2 (1) CHRNA4 (1) Tubulin (1) OPRM1 (1) CD274 (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.